Inhibikase Therapeutics, Inc.
IKT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.17 | 0.17 | 0.30 | 0.06 |
| FCF Yield | -6.95% | -3.18% | -2.09% | -2.37% |
| EV / EBITDA | -8.43 | -8.76 | -7.79 | -13.08 |
| Quality | ||||
| ROIC | -17.52% | -13.52% | -17.00% | -13.60% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.89 | 0.56 | 0.30 | 0.44 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -81.92% | -35.84% | 23.24% | -9.52% |
| Safety | ||||
| Net Debt / EBITDA | 3.00 | 6.96 | 4.66 | 4.36 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -10,072.44 | -12,034.50 | 0.00 |